Is hydroxyzine safe for an older adult (≥65 years) with delirium, antipsychotic sensitivity, high aspiration risk, and abnormal breathing patterns?

Hydroxyzine Should Be Avoided in This Clinical Scenario

Hydroxyzine is contraindicated in this older patient with delirium, abnormal breathing patterns, and high aspiration risk due to significant risks of respiratory depression, CNS depression, QT prolongation, and anticholinergic effects that can worsen delirium.

Critical Safety Concerns

Respiratory Depression Risk

The FDA label explicitly warns that hydroxyzine potentiates CNS depressants and requires dose reduction when used with other sedating agents 1. In a patient already exhibiting Cheyne-Stokes breathing (abnormal respiratory pattern), adding hydroxyzine creates unacceptable risk for:

• Further respiratory depression
• Oxygen desaturation
• Potential need for intubation

The high aspiration risk is particularly concerning given hydroxyzine's sedative properties, which can impair protective airway reflexes and swallowing mechanisms.

Anticholinergic Properties and Delirium

The 2019 AGS Beers Criteria explicitly recommends avoiding antihistamines in older adults due to their anticholinergic properties 2. While hydroxyzine has been studied for delirium treatment 3, 4, these studies examined its use as a treatment for delirium, not in patients with pre-existing delirium plus multiple high-risk features. The anticholinergic burden can:

• Worsen existing delirium
• Cause confusion and oversedation in elderly patients 1
• Impair cognition despite some preservation of memory at low doses 5

QT Prolongation

The FDA label warns of QT prolongation and Torsade de Pointes risk, particularly in patients with:

• Pre-existing heart disease
• Electrolyte imbalances
• Concomitant use of other QT-prolonging drugs 1

This is especially relevant given the patient's "antipsychotic sensitivity," as many antipsychotics also prolong QT interval, and hydroxyzine would compound this risk.

Evidence-Based Alternatives

Preferred Approach for Agitated Delirium

The 2025 GEDG systematic review provides clear guidance for older adults with severe agitation 6:

First-line strategy:

• Nonpharmacologic approaches are mandatory - person-centered communication, sensory therapy, environmental modifications
• Serious adverse events occurred in 16.8% of older adults receiving antipsychotic or anxiolytic medications

If pharmacologic intervention is unavoidable:

• Oral quetiapine has the best safety profile among studied medications 6
• Start with the lowest effective dose
• Avoid benzodiazepines (midazolam showed excessive risk; lorazepam showed dose-dependent respiratory adverse events) 6
• Avoid parenteral routes when possible - oral administration significantly reduces adverse events 6

Specific to This Patient's Profile

Given the constellation of:

1. Delirium - requires avoidance of anticholinergics
2. Antipsychotic sensitivity - limits typical first-line options
3. High aspiration risk - requires avoiding sedation
4. Abnormal breathing - respiratory depressants are contraindicated

The safest approach is:

1. Maximize nonpharmacologic interventions aggressively
2. If medication is absolutely necessary for safety, consider low-dose oral quetiapine (12.5-25 mg) with close respiratory monitoring, as it has the most favorable safety profile in geriatric agitation 6
3. Avoid all antihistamines including hydroxyzine
4. Avoid benzodiazepines given respiratory concerns 6

Common Pitfalls to Avoid

• Do not use hydroxyzine as a "safer alternative" to antipsychotics - it carries its own significant risks in this population
• Do not assume antihistamines are benign - the AGS Beers Criteria explicitly warns against their use in older adults 2
• Do not combine sedating agents - the 2025 GEDG data strongly advise against co-administration of antipsychotics and benzodiazepines, and this extends to antihistamines 6
• Do not use parenteral routes unless absolutely necessary - oral administration reduces adverse events significantly 6

Clinical Bottom Line

Hydroxyzine poses unacceptable risks in this specific clinical scenario due to the convergence of respiratory compromise, aspiration risk, pre-existing delirium, and anticholinergic burden. The FDA warnings about CNS depression, respiratory effects, and use in elderly patients 1, combined with AGS Beers Criteria recommendations against antihistamines 2, make this a clear contraindication. Prioritize nonpharmacologic management, and if pharmacologic intervention is unavoidable for safety, use the lowest dose of oral quetiapine with intensive monitoring.